# A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis

> **NCT00035529** · PHASE2 · TERMINATED · sponsor: **Bristol-Myers Squibb**

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Placebo
- **DRUG:** BMS 188667 (Abatacept)
- **DRUG:** BMS 188667 (Abatacept)

## Key facts

- **NCT ID:** NCT00035529
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-11
- **Primary completion:** 2003-12
- **Final completion:** 2003-12
- **Target enrollment:** — (—)
- **Last updated:** 2010-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00035529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00035529, "A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00035529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*